Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hypertension

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 57 articles:
HTML format
Text format



Single Articles


    March 2017
  1. LUYCKX VA, Perico N, Somaschini M, Manfellotto D, et al
    A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group.
    Lancet. 2017 Mar 8. pii: S0140-6736(17)30576.
    PubMed     Text format    


    February 2017
  2. GRADMAN AH
    A quarter-dose quadpill for initial treatment of hypertension.
    Lancet. 2017 Feb 9. pii: S0140-6736(17)30331.
    PubMed     Text format    


  3. CHOW CK, Thakkar J, Bennett A, Hillis G, et al
    Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
    Lancet. 2017 Feb 9. pii: S0140-6736(17)30260.
    PubMed     Text format     Abstract available


    January 2017
  4. BLACHER J, Levy BI, Mourad JJ, Safar ME, et al
    Hypertension control and cardiovascular disease - Authors' reply.
    Lancet. 2017;389:154-155.
    PubMed     Text format    


  5. JAMES JE
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:154.
    PubMed     Text format    


  6. MESSERLI FH, Fischer U, Rimoldi SF, Bangalore S, et al
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:153.
    PubMed     Text format    


  7. ZENG X, Deng A, Ding Y
    The INTERSTROKE study on risk factors for stroke.
    Lancet. 2017;389:35.
    PubMed     Text format    


    December 2016
  8. SLIWA K
    The heart of Africa: succeeding against the odds.
    Lancet. 2016;388:e28-e36.
    PubMed     Text format     Abstract available


    October 2016
  9. SCHOFIELD G, Henderson G, Crofts C
    Beyond salt-where next for hypertension epidemiology?
    Lancet. 2016;388:2110-2111.
    PubMed     Text format    


  10. MENTE A, O'Donnell MJ, Yusuf S
    Sodium and cardiovascular disease - Authors' reply.
    Lancet. 2016;388:2113-2114.
    PubMed     Text format    


  11. CAPPUCCIO FP
    Sodium and cardiovascular disease.
    Lancet. 2016;388:2112.
    PubMed     Text format    


  12. KATZ J
    Sodium and cardiovascular disease.
    Lancet. 2016;388:2112-2113.
    PubMed     Text format    


  13. STRAZZULLO P, Giampaoli S, Iacoviello L, Rossi L, et al
    Sodium and cardiovascular disease.
    Lancet. 2016;388:2111.
    PubMed     Text format    


  14. WALD N, Law M
    Sodium and cardiovascular disease.
    Lancet. 2016;388:2111-2112.
    PubMed     Text format    


  15. ALDERMAN MH
    Dietary sodium: paradigm shifts from public health to clinical medicine.
    Lancet. 2016;388:2110.
    PubMed     Text format    



  16. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.
    Lancet. 2016;388:1659-1724.
    PubMed     Text format     Abstract available


    September 2016
  17. WATTS G
    Neil Poulter: upping the pressure on hypertension.
    Lancet. 2016 Sep 29. pii: S0140-6736(16)31775.
    PubMed     Text format    


  18. OLSEN MH, Angell SY, Asma S, Boutouyrie P, et al
    A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension.
    Lancet. 2016 Sep 22. pii: S0140-6736(16)31134.
    PubMed     Text format    


    August 2016
  19. MANCIA G
    Should blood pressure reduction be aggressive in patients with hypertension and coronary artery disease?
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31398.
    PubMed     Text format    


  20. VIDAL-PETIOT E, Ford I, Greenlaw N, Ferrari R, et al
    Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31326.
    PubMed     Text format     Abstract available


  21. WALLENTIN L, Lindhagen L, Arnstrom E, Husted S, et al
    Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31276.
    PubMed     Text format     Abstract available


    July 2016
  22. KAIN K
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:126.
    PubMed     Text format    


  23. ETTEHAD D, Emdin CA, Kiran A, Rahimi K, et al
    Blood pressure lowering for cardiovascular disease - Authors' reply.
    Lancet. 2016;388:126-7.
    PubMed     Text format    


  24. O'KEEFFE DT, Maraka S
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    PubMed     Text format    


  25. SMULDERS YM, Muller M
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125-6.
    PubMed     Text format    


  26. COLLINS DR, Albasri A, O'Sullivan J, Bobrovitz N, et al
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    PubMed     Text format    


    June 2016
  27. SONODA Y, Higuchi A, Morita T, Mori J, et al
    Intensive blood pressure lowering.
    Lancet. 2016;387:2291.
    PubMed     Text format    


  28. XIE X, Atkins E, Lv J, Rodgers A, et al
    Intensive blood pressure lowering - Authors' reply.
    Lancet. 2016;387:2291.
    PubMed     Text format    


    May 2016
  29. OK E, Asci G, Chazot C, Ozkahya M, et al
    Controversies and problems of volume control and hypertension in haemodialysis.
    Lancet. 2016 May 20. pii: S0140-6736(16)30389.
    PubMed     Text format     Abstract available


  30. MENTE A, O'Donnell M, Rangarajan S, Dagenais G, et al
    Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies.
    Lancet. 2016 May 20. pii: S0140-6736(16)30467.
    PubMed     Text format     Abstract available


    April 2016
  31. WILLIAMS B, MacDonald TM, Morant SV, Brown MJ, et al
    PATHWAY-2: spironolactone for resistant hypertension - Authors' reply.
    Lancet. 2016;387:1373-4.
    PubMed     Text format    


  32. DALE A, Hartley P, Goldacre B
    PATHWAY-2: spironolactone for resistant hypertension.
    Lancet. 2016;387:1372-3.
    PubMed     Text format    


  33. GKALIAGKOUSI E, Gavriilaki E, Triantafyllou A, Douma S, et al
    PATHWAY-2: spironolactone for resistant hypertension.
    Lancet. 2016;387:1372.
    PubMed     Text format    


  34. BOUTARI C, Stavropoulos K, Imprialos K, Doumas M, et al
    PATHWAY-2: spironolactone for resistant hypertension.
    Lancet. 2016;387:1371-2.
    PubMed     Text format    


  35. ZALCMAN G, Mazieres J, Margery J, Greillier L, et al
    Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Lancet. 2016;387:1405-14.
    PubMed     Text format     Abstract available


    March 2016
  36. LAURENT S, Boutouyrie P
    Blood pressure lowering trials: wrapping up the topic?
    Lancet. 2016;387:923-4.
    PubMed     Text format    


    February 2016
  37. BLACHER J, Levy BI, Mourad JJ, Safar ME, et al
    From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century.
    Lancet. 2016 Feb 5. pii: S0140-6736(16)00002.
    PubMed     Text format    


    January 2016
  38. BRUNSTROM M, Carlberg B
    Lower blood pressure targets: to whom do they apply?
    Lancet. 2016;387:405-6.
    PubMed     Text format    


    December 2015
  39. ETTEHAD D, Emdin CA, Kiran A, Anderson SG, et al
    Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.
    Lancet. 2015 Dec 23. pii: S0140-6736(15)01225.
    PubMed     Text format     Abstract available



  40. Health security: the defining challenge of 2016.
    Lancet. 2015;386:2445.
    PubMed     Text format    


    November 2015
  41. LOBO MD, Sobotka PA, Dolan E, Witkowski A, et al
    Central arteriovenous anastomosis and hypertension - Authors' reply.
    Lancet. 2015;386:1821-2.
    PubMed     Text format    


  42. DEINUM J, Wetzels JF
    Central arteriovenous anastomosis and hypertension.
    Lancet. 2015;386:1821.
    PubMed     Text format    


  43. XIE X, Atkins E, Lv J, Bennett A, et al
    Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.
    Lancet. 2015 Nov 7. pii: S0140-6736(15)00805.
    PubMed     Text format     Abstract available


    October 2015
  44. BROEKHUIJSEN K, Groen H, van den Berg PP, Mol BW, et al
    Gestational hypertension and advanced maternal age - Authors' reply.
    Lancet. 2015;386:1628.
    PubMed     Text format    


  45. DIETL A, Farthmann J
    Gestational hypertension and advanced maternal age.
    Lancet. 2015;386:1627-8.
    PubMed     Text format    


  46. ROSSIGNOL P, Massy ZA, Azizi M, Bakris G, et al
    The double challenge of resistant hypertension and chronic kidney disease.
    Lancet. 2015;386:1588-98.
    PubMed     Text format     Abstract available


    September 2015
  47. AZIZI M, Pereira H, Bobrie G, Gosse P, et al
    Renal denervation for resistant hypertension - Authors' reply.
    Lancet. 2015;386:1240.
    PubMed     Text format    


  48. MIRCHEVA M, Neuhofer W, Popa C, Kramer BK, et al
    Renal denervation for resistant hypertension.
    Lancet. 2015;386:1239-40.
    PubMed     Text format    


  49. STERNLICHT H, Bakris GL
    Spironolactone for resistant hypertension-hard to resist?
    Lancet. 2015 Sep 18. pii: S0140-6736(15)00264.
    PubMed     Text format    


  50. WILLIAMS B, MacDonald TM, Morant S, Webb DJ, et al
    Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
    Lancet. 2015 Sep 18. pii: S0140-6736(15)00257.
    PubMed     Text format     Abstract available


  51. GRANGE S, Bekri S, Artaud-Macari E, Francois A, et al
    Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency.
    Lancet. 2015;386:1011-2.
    PubMed     Text format    


    August 2015
  52. OLSEN MH, Spencer S
    A global perspective on hypertension: a Lancet Commission.
    Lancet. 2015;386:637-8.
    PubMed     Text format    


    May 2015
  53. JAFAR TH, Assam PN
    Dual RAAS blockade for kidney failure: hope for the future.
    Lancet. 2015;385:2018-20.
    PubMed     Text format    


  54. PALMER SC, Mavridis D, Navarese E, Craig JC, et al
    Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis.
    Lancet. 2015;385:2047-56.
    PubMed     Text format     Abstract available


  55. BONITA R, Beaglehole R
    A public health approach to hypertension.
    Lancet. 2015;385:1834.
    PubMed     Text format    


  56. SHELTON JD
    A public health approach to hypertension.
    Lancet. 2015;385:1833-4.
    PubMed     Text format    


  57. ORDUNEZ P, Luciani S, Barojas A, Fitzgerald J, et al
    A public health approach to hypertension.
    Lancet. 2015;385:1833.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hypertension is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: